Leukocyte-technetium-99m uptake in Crohn’s disease: Does it show subclinical disease?

Table 1 Summary of data from patients with CD

Patients (sex, yr)	CDAI	Vienna classification	SI	CRP (mg/L)	Treatment
I.M.F. (M, 41)	330.0	A1L1B2	11	30.0	Methotrexate
A.A.A. (M, 40)	53.4	A1L1B2	4	2.1	Prednisone
J.A.N. (M, 44)	2.0	A1L1B3	0	4.0	Prednisone, mesalazine, azathioprine
L.M.T.(F, 54)	59.3	A2L1B1	5	7.3	Prednisone, azathioprine
L.J.O. (F, 37)	126.6	A1L4B1	0	12.0	Mesalazine, azathioprine
T.F.C. (M, 24)	56.3	A1L3B2	0	9.2	Without medication
F.R.F. (F, 44)	52.6	A1L1B1	2	2.5	Prednisone, mesalazine, azathioprine
A.A.S. (F, 24)	1.7	A1L1B1	3	6.0	Mesalazine
L.D. (F, 24)	47.1	A1L1B1	8	34.1	Azathioprine
A.F.S. (F, 35)	62.9	A1L3B3	5	3.0	Prednisone, mesalazine, ciprofloxacin, azathioprine, infliximab
L.P.M. (M, 38)	146.6	A1L1B1	3	17.5	Prednisone, mesalazine
M.O.R. (F, 30)	197.4	A1L3B3	4	6.0	Hydrocortisone, mesalazine, ceftriaxone, azathioprine
G.E.S.F.(M, 37)	162.1	A1L1B3	5	16.0	Sulfasalazine, ciprofloxacin/metronidazole, thalidomide
E.C.S. (F, 31)	122.1	A1L1B3	3	8.0	Prednisone, ciprofloxacin, azathioprine
J.G.R. (M, 41)	97.5	A1L1B3	3	6.0	Prednisone, mesalazine, azathioprine
J.D.G. (F, 52)	126.2	A1L2B2	3	14.0	Prednisone, mesalazine
R.M.M.(F, 2)	73.4	A1L1B1	0	6.1	Azathioprine
A.B.O. (F, 58)	81.3	A2L3B1	2	2.5	Mesalazine
M.F.L. (F, 46)	84.3	A1L1B2	3	48.0	Prednisone
M.J.A. (F, 51)	179.9	A2L1B1	2	3.2	Mesalazine, azathioprine

CD: Crohn's disease; CDAI: Crohn’s Disease Activity Index; SI: Scintigraphic index; CRP: C-reactive protein.

Table 2 Spearman’s rank correlation (n = 20)

	Spearman’s rank	Correlation coefficient (ρ)
		t	P
CDAI and SI	0.1835	0.7918	0.4388
CDAI and CRP	0.3373	1.5204	0.1457
SI and CRP	0.2783	1.2293	0.2347